PWM
IRLA

Prentice Wealth Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Prentice Wealth Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$1K – 155
2022
Q2 		$1K Buy
+2
New +$1.41K ﹤0.01% 133
2021
Q4 		– Hold
0
– -$6K – 254
2021
Q3 		– Hold
0
– – – 271
2021
Q2 		– Hold
0
– – – 286
2021
Q1 		– Hold
0
– – – 289

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Prentice Wealth Management's IRLA Position: Q3 2022 in Review

Prentice Wealth Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2022, closing a stake of 2 shares — an estimated $1K sold.

Prentice Wealth Management first reported a position in IRLA in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 58 funds tracked by Wall St. Rank hold IRLA as of Q3 2022.

  • Prentice Wealth Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Prentice Wealth Management sold 2 IRulya Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • Prentice Wealth Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Prentice Wealth Management's IRulya Therapeutics Inc. Common Stock position peaked at $1K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2022.

Based on Prentice Wealth Management's 13F filing for Q3 2022, filed 19 Oct 2022.